MEDICATIONS

Card Set Information

Author:
gabby_samaniego
ID:
163033
Filename:
MEDICATIONS
Updated:
2012-07-27 21:25:12
Tags:
meds
Folders:

Description:
meds
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user gabby_samaniego on FreezingBlue Flashcards. What would you like to do?


  1. ATENOLOL (Ternormin)
    • Classification
    •      Beta blockers
    •      Antianginals
    •      Antihypertensives

    • Indication
    •      Management of HTN
    •      Management of angina pectoris
    •      Prevention of MI

    • Effects
    •      Decrease BP and HR
    •      Decrease frequency of attacks of angina pectoris
    •      Prevention of MI
  2. METOPROLOL (Lopressor)
    • Classification
    •      Beta blockers
    •      Antianginals
    •      Antihypertensives

    • Indication
    •      HTN
    •      Angina pectoris
    •      Prevention of MI and decreased mortality in pt w/      
    •      recent MI
    •      Management of stable, symptomatic HF d/t ischemic,      
    •      hypertensive or cardiomyopathic origin

    • Effects
    •      Decrease BP and HR
    •      Decrease frequency of attacks of angina pectoris
    •      Decrease rate of cardiovascular mortality and
    •      hospitalization in pt w/ HF
  3. CARVEDILOL (Coreg)
    • Classification
    •      Beta blockers
    •      Antihypertensives

    • Indication
    •      HTN
    •      CHF (ischemic or cardiomyopathic) w/ digoxin,
    •      diuretics, and ACE inhibitors
    •      Left ventricular dysfunction after myocardial infarction

    • Effects
    •      Decrease HR and BP
    •      Improve cardiac output, slowing of the progression of
    •      CHF and decreased risk of death
  4. LABETALOL (Trandate)
    • Classification
    •      Beta blockers
    •      Antianginals
    •      Antihypertensives

    • Indication
    •      Management of HTN

    • Effects
    •      Decrease BP
  5. PROPANOLOL (Inderal)
    • Classification
    •      Beta blocker
    •      Antianginal
    •      Antiarrhythmics
    •      Antihypertensives
    •      Vascular headache suppressants

    • Indication
    •      Management of HTN, angina, arrythmias,
    •      hypertrophic cardiomyopathy, thyotoxicosis, essential
    •      tremors, pheochromocytoma
    •      Also used in the prevention of MI, and of vascular
    •      headaches

    • Effects
    •      Decrease HR and BP
    •      Suppression  of arrhythmias
    •      Prevention of MI
  6. CAPTOPRIL (Capoten)
    • Classification
    •     Ace inhibitor
    •      Antihypertensives

    • Indication
    •      Alone or w/ other agents in the management of HTN
    •      Management of HF
    •      Reduction of risk of death, HF-related hospitalizations,
    •      and development of overt HF following MI
    •      RX of diabetic nephropathy in pt w/ type 1 DM and
    •      retinopathy

    • Effects
    •      Lowering of BP in pt w/ HTN
    •      Improve survival and reduced sx in pt w/ HF
    •      Improve survival and reduced development of overt
    •      HF after MI
    •      Decrease progression of diabetic nephropathy w/
    •      decrease need for transplantation of dialysis
  7. ENALAPRIL (Vasotec)
    • Classification
    •     Ace inhibitors
    •     Antihypertensives

    • Indication
    •      Alone or w/ other agents in the management of HTN
    •      Management of symptomatic HF
    •      Slowed progression of asymptomatic left ventricular
    •      dysfunction to overt HF

    • Effects
    •      Lowering of BP in pt w/ HTN
    •      Increase survival and reduction of sx in pt w/
    •      symptomatic HF
    •      Decreased development of overt HF
  8. LISINOPRIL (Prinivil, Zastril)
    • Classification
    •      Ace inhibitors
    •      Antihypertensives

    • Indication
    •      Alone or w/ other agents in the management of HTN
    •      Management of HF
    •      Reduction of risk of death or development of HF after
    •      MI

    • Effects
    •      Lowering of BP in pt w/ HTN
    •      Increase survival and decrease sx in pt w/ HF
    •      Increased survival after MI
  9. DILTIAZEM (Cardizem)
    • Classification
    •      Calcium channel blockers
    •      Antianginals
    •      Antiarrhythmics
    •      Antihypertensives

    • Indication
    •      HTN
    •      Angina Pectoris and vasospastic (Prinsmetal's) angina
    •      Supraventricular tachyarrhythmias and rapid
    •      ventricular rates in A flutter or fib

    • Effects
    •      Systemic vasodilation resulting in decrease BP
    •      Coronary vasodilation resulting in decreased frequency
    •      and severity of attacks of angina
    •      Reduction of ventricular rate in A flutter or fib
  10. NIFEDIPINE (Procardia)
    • Classification
    •      Calcium channel blockers
    •      Antianginals
    •      Antihypertensives

    • Indication
    •      Management of HTN (extended release only)
    •      Management of angina pectoris
    •      Management of vasospastic (Prinsmetal's) angina

    • Effects
    •      Systemic vasodilation, resulting in decrease BP
    •      Coronary vasodilation, resulting in decrease frequency
    •      and severity of attacks of angina
  11. VERAPAMIL (Isoptin, Calan)
    • Classification
    •      Calcium channel blockers
    •      Antianginals
    •      Antiarrhythmics
    •      Antihypertensives
    •      Vascular headache suppresants

    • Indication
    •      Management of HTN, angina pectoris, and/ or
    •      vasospastic (Prinzmetal's) angina
    •      Management of supraventricular arrhythmias and repid
    •      ventricular rates in a flutter or fib

    • Effects
    •      Systemic vasodilation resulting in decrease BP
    •      Coronary vasodilation resulting in decreased frequency
    •      and severity of attacks of angina
    •      Reduction of ventricular rate during a fib or flutter
  12. LOVASTATIN (Mevacor)
    • Classification
    •      Lipid-lowering agent
    •      HMG COA reductase inhibitors (statin)

    • Indication
    •      Adjunctive management of primary
    •      hypercholesterolemia and mixed dyslipidemias
    •      Primary prevention of coronary heart disease (MI,
    •      unstable angina, and coronary revascularization) in
    •      asymptomatic pts w/ increased total and low- density
    •      lipoprotein (LDL) cholesterol and decreased high-
    •      density lipiprotein (HDL) cholesterol
    •      Slows the progression of coronary atherosclerosis in
    •      pts w/ coronary artery dz

    • Effects
    •      Lowering of total and LDL cholesterol and
    •      triglycerides.  Slighty increases HDL cholersterol
    •      Slows the progression of coronary atherosclerosis w/
    •      resultant decrease in coronary heart disease- related
    •      events
  13. ATORVASTATIN (Lipitor)
    • Classification
    •      Lipid-lowering agent     
    •      HMG COA reductase inhibitors (statin)

    • Indication
    •      Adjunctive management of primary      
    •      hypercholesterolemia and mixed dyslipidemias
    •      Primary prevention of coronary heart disease (MI,      
    •      unstable angina, and coronary revascularization) in      
    •      asymptomatic pts w/ increased total and low- density      
    •      lipoprotein (LDL) cholesterol and decreased high-      
    •      density lipiprotein (HDL) cholesterol

    • Effects
    •      Lowering of total and LDL cholesterol and      
    •      triglycerides.  Slighty increases HDL cholersterol   
    •      Reduction of lipids/ cholesterol reduces the risk of MI
    •      and stroke sequelae 
    •      Slows the progression of coronary atherosclerosis w/      
    •      resultant decrease in coronary heart disease- related      
    •      events
  14. SIMVASTATIN (Zocor)
    • Classification
    •      Lipid-lowering agents
    •      HMG COA reductase inhibitor (statin

    • Indication
    •      Adjunctive management of primary
    •      hypercholesterolemia and mixed dyslipidemias
    •      Secondary prevention of myocardial infarction,
    •      coronary revascularization, stroke, and cardiovascular
    •      mortality in pts w/ clinically evident coronary heart dz

    • Effects
    •      Lowering of total and LDL cholesterol and
    •      triglycerides.  Slightly increases HDL cholesterol
    •      Slows the progression of coronary atherosclerosis w/
    •      resultant decrease in coronary heart disease-related
    •      events
  15. NIACIN
    • Classification
    •      Lipid-lowering agents
    •      Water soluble vitamins

    • Indication
    •      Treatment and prevention of niacin deficiency
    •      (Pellagra)
    •      Adjunctive therapy in certain hyperlipidemias (niacin
    •      only)

    • Effects
    •      Decrease blood lipids (niacin only)
    •      Supplementation in dificiency states
  16. ALDACTONE (Spironolactone)
    • Classification
    •      Diuretics
    •      Potassium-sparing diuretic

    • Indication
    •      Management of primary hyperaldosteronism
    •      Management of edema associated w/ CHF, cirrhosis
    •      and nephrotic syndrome
    •      Management of essential hypertension
    •      Treatment of hypokalemia (counteracts potassium loss
    •      caused by other diuretics

    • Effects
    •      Increase survival in pt w/ severe HF
    •      Weak diuretic and antihypertensive response when
    •      compared w/ other diuretics
    •      Conservation of potassium
  17. LASIX (Furosemide)
    • Classification
    •      Diuretics
    •      Loop diuretics

    • Indication
    •      Edema d/t HF, hepatic impairment, or renal disease
    •      HTN

    • Effect
    •      Diuresis and subsequent mobilization of excess fluid
    •      (edema, pleural effusions)
    •      Decrease BP
  18. ISOSORBIDE
    • Classification
    •      Antianginals
    •      Nitrates

    • Indication
    •      Acute treatment of anginal attacks
    •      Prophylactic management of angina pectoris
    •      Treatment of chronic CHF

    • Effect
    •      Produce vasodilation
    •      Relief and prevention of anginal attacks
  19. COLACE (DOCUSATE)
    • Classification
    •      Laxative
    •      Stool softener

    • Indication
    •      PO: Prevention of constipation (in pt who should
    •      avoid straining, such as after MI or rectal surgery
    •      RECT: Used as enema to soften fecal impaction

    • Effect
    •      Softening and passage of stool
  20. SENOKOT (Sennosides)
    • Classification
    •      Laxative
    •      Stimulant laxative

    • Indication
    •      Treatment of constipation, particularly when associated
    •      w/:
    •           Slow transit time
    •           Constipating drugs
    •           Irritable or spastic bowel syndrome
    •           Neurologic constipation

    • Effect
    •      Laxative action
  21. ACETOMINOPHEN (Tylenol)
    • Classification
    •      Antipyretics
    •      Nonopioid analgesics

    • Indication
    •      Mild pain
    •      Fever

    • Effect
    •      Has no significant anti-inflammatory properties or GI
    •      toxicity
    •      Analgesia
    •      Antipyresis
  22. MORPHINE
    • Classification
    •      Opioid analgesics/ agonists

    • Indication
    •      Severe pain
    •      Pulmonary edema
    •      Pain associated with MI

    • Effect
    •      Decrease in severity of pain
  23. OXYCODONE (Oxycontin)
    • Classification
    •      Opioid analgesics/ agonists

    • Indication
    •      Moderate to severe pain

    • Effect
    •      Decrease pain
  24. FENTANYL
    •      Classification
    •           Opioid analgesics/ agonists

    • Oral transmucosal
    •      Indication
    •           Management of breakthrough cancer pain in pts w/
    •           malignancies who are already recieving and are
    •           tolerant to opioid therapy for their underlying
    •           cancer pain

    •      Effect
    •           Decrease pain

    • Parenteral
    •      Indication
    •           Analgesic supplement to general anesthesia; usually
    •           w/ other agents to produce balanced anesthesia

    •      Effect
    •           Supplement in anesthesia
    •           Decrease pain

    • Sublingual
    •      Indication
    •           Management of breakthrough pain in opioid-
    •           tolerant cancer pts >= 18 yr who already recieve
    •           opioids for persistent cancer-related pain

    •      Effect
    •           Decrease breakthrough pain during chronic opioid
    •           therapy

    • Transdermal
    •      Indication
    •           Moderate to severe chronic pain requiring
    •           continuous opioid analgesic therapy for an
    •           extended time at a dose of 25 mcg/hr or more of the
    •           transdermal system.
    •           Transdermal fentanyl is not recommended for the
    •           control of postoperative, mild, or intermittent pain,
    •           nor should it be used for short-term pain relief.

    •      Effect
    •           Decrease in severity of chonic pain
  25. METHADONE
    • Classification
    •      Opioid analgesics/ agonists

    • Indication
    •      Severe pain
    •      Suppresses withdrawal symptoms in opioid
    •      detoxification
    •      Neonatal abstinence syndrome

    • Effect
    •      Decrease in severity of pain
    •      Suppression of withdrawal symptoms during
    •      detoxification and maintenance from heroin and other
    •      opioids
  26. DEMEROL (Meperidine)
    • Classification
    •      Opioid analgesic/ agonist

    • Indication
    •      Moderate or severe pain (alone or w/ nonopioid
    •      agents)
    •      Anesthesia adjunct
    •      Analgesic during labor
    •      Preoperative sedation

    • Effect
    •      Decrease in severity of pain
  27. DILAUDID (Hydromorphone)
    • Classification
    •      Opioid agonists/ analgesic
    •      Allergy, cold and cough remedies (antitussive)

    • Indication
    •      Moderate to severe pain (alone and in combo w/
    •      nonopioid analgesics); extended release product for
    •      opioid-tolerant pts requiring around-the-clock
    •      management of persistent pain
    •      Antitussive (lower doses)

    • Effect
    •      Deacrease in moderate to severe pain
    •      Suppression of cough
  28. NORCO (Hydrocodone)
    • Classification
    •      Opioid agonist/ analgesic
    •      Allergy, cold and cough remedies (antitussive)

    • Indication
    •      Used mainly in combo w/ nonopioid analgesics
    •      (acetaminophen/ ibuprofen) in the management of
    •      moderate to severe pain
    •      Antitussive (usually in combo products w/
    •      decongestants)

    • Effect
    •      Decrease in severity of moderate pain
    •      Suppression of the cough reflex
  29. VICODIN (Hydrocodone + Acetaminophen)
    • Classification
    •      Opioid agonist/ analgesic
    •      Allergy, cold and cough remedies (antitussive)

    • Indication
    •      Used mainly in combo w/ nonopioid analgesics      
    •      (acetaminophen/ ibuprofen) in the management of      
    •      moderate to severe pain
    •      Antitussive (usually in combo products w/      
    •      decongestants)

    • Effect
    •      Decrease in severity of moderate pain
    •      Suppression of the cough reflex
  30. PERCOCET (Oxycodone Combunox)
    • Classification
    •     Opioid analgesic/ agonist

    • Indication
    •      Moderate to severe pain

    • Effect
    •      Decrease pain
  31. BUTORPHANOL (Stadol)
    • Classification
    •      Opioid analgesic/ agonist antogonist

    • Indication
    •      Management of moderate to severe pain
    •      Analgesia during labor
    •      Sedation before surgery
    •      supplement in balanced anesthesia

    • Effect
    •      Decrease severity of pain
  32. NALBUPHINE (Nubain)
    • Classification
    •      Opioid analgesic/ agonist

    • Indication
    •      Moderate to severe pain
    •      Analgesia during labor
    •      Sedation before surgery
    •      Supplement to balanced anesthesia

    • Effect
    •      Decrease pain
  33. IBUPROFIN (Advil, Motrin)
    • Classification
    •      Nonsteroidal anti-inflammatory agents
    •      Antipyretics
    •      Antirheumatics
    •      Nonopioid analgesic

    • Indication
    •      Mild to moderate pain or dysmenorrhea
    •      Inflammatory disorders including:
    •           Rheumatoid arthritis (including juvenile)
    •           Osteoarthritis
    •      Lowering of fevere

    • Effect
    •      Decrease pain and inflammation
    •      Reduction of fever
  34. ASPIRIN
    • Classification
    •      Antipyretics
    •      Nonopioid analgesic
    •      Salicylate

    • Indication
    •      Inflammatory disorders including:
    •           Rheumatoid arthritis
    •           Osteoarthritis
    •      Mild to moderate pain
    •      Fever
    •      Prophylaxis of transient ischemic atttacks and MI

    • Effect
    •      Analgesia
    •      Reduction of inflammation
    •      Reduction of fever
    •      Decrease incidence of transient ischemic attacks and
    •      MI
  35. KETOROLAC (Toradol)
    • Classification
    •      Nonsteroidal anti-inflammatory agents
    •      Nonopioid analgesic
    •      Pyrroziline carboxylic acid

    • Indication
    •      Short term management of pain (not to exceed 5 days
    •      total for all routes combined)

    • Effect
    •      Decrease pain
  36. INDOMETHACIN (Indocin)
    • Classification
    •      Antirheumatics
    •      Ductus arteriosus pateny adjuncts (IV only)
    •      Nonsteroidal anti-inflammatory agent

    • Indication
    •      PO
    •           Inflammatory disorders including:
    •                Rheumation arthritis
    •                Gouty arthritis
    •                Osteoarthritis
    •                Ankylosing spondylitis
    •           Generally reserved for pt who do not respond to
    •           less toxic agents
    •      IV
    •           Alternative to surgery in the management of paten
    •           ductus arteriosus (PDA) in premature neonates

    • Effect
    •      PO
    •           Suppression of pain and inflammation
    •      IV
    •           Closure of PDA
  37. AMOXICILLIN
    • Classification
    •      Anti-infectives
    •      Antiulcer agents
    •      Aminopenicillins

    • Indication
    •      Treatment of:
    •           Skin and skin structure infections
    •           Otitis media
    •           Sinusitis
    •           Respiratory infections
    •           Genitourinary infections
    •      Endocarditis prophylaxis
    •      Postexposure inhalational anthrax prophylaxis
    •      Management of ulcer disease due to H. Pylori

    • Effect
    •      Bactericidal action; spectrum is broader than penicillin
    •      Binds to bacterial cell wall, causing cell death
  38. ANCEF (Cefazolin)
    • Classification
    •      Anti-infectives
    •      First generation cephalosporins

    • Indication
    •      Treatment of the following infections d/t susceptible
    •      organisms:
    •           Skin and skin structure infections (including burn
    •           wounds)
    •           Pneumonia
    •           UTI
    •           Biliary tract infections
    •           Genital infections
    •           Bone and joint infections
    •           Septicemia
    •           Bacterial endocarditis prophylaxis for dental and
    •           upper respiratory procedures
    •      Perioperative prophylaxis
    •      Not suitable for the treatment of meningitis

    • Effect
    •      Bactericidal action against susceptible bacteria

What would you like to do?

Home > Flashcards > Print Preview